Advances in targeted therapy for melanoma.

摘要: Metastatic melanoma remains an aggressive malignancy conferring a very poor prognosis, and standard chemotherapeutic immunologic treatments have not demonstrated overall survival benefit. No molecularly targeted therapy is approved for the treatment of advanced melanoma. Melanoma heterogeneous malignancy, optimal in given patient likely to depend on presence specific molecular abnormalities. Aberrations components signal transduction pathways been identified that modulate proliferation survival. Mutations activate mitogen activated protein kinase (MAPK) pathway via BRAF or NRAS are present majority melanomas arising skin intermittently exposed sun. KIT oncogene more commonly from mucosal, acral, chronic sun-damaged sites. Inhibitors MAPK currently undergoing clinical investigation. In this article, we review advances strategies treat different subgroups patients with